ADG-106 is a fully human monoclonal antibody targeting CD137 (4-1BB). It activates CD137 via potent FcgammaRIIB-mediated cross-linking, antagonising CD137 ligands, and may be employed for anti-tumour immunotherapy.
Purity:
95.00%
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted
